Press Release FeedGet the RSS feed
Menu

Business Wire

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Business Wire

Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations

Signatera™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera's ESMO program

AUSTIN, Texas, October 18, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.

New evidence highlights the power of Natera's latest ultrasensitive molecular residual disease (MRD) technology, Signatera Genome with Phased and Structural Variants, which has demonstrated an industry-leading analytical limit of detection (LOD95) below 1 part per million (ppm), and detection observed significantly below 1 part per 10 million.1

Spanning tumor types and treatment modalities, multiple ESMO presentations will show that serial ctDNA testing provides meaningful clinical benefit:

  • ICONIC trial in gastroesophageal cancer (abstract 2901P): Among patients treated with perioperative chemotherapy and immunotherapy, MRD clearance during neoadjuvant therapy was strongly associated with a lower risk of recurrence and a favorable pathologic response. Signatera Genome with Phased and Structural Variants detected all evaluable recurrences during surveillance, with a >7.3 month median lead time over standard imaging.

  • SAGITTARIUS trial in colon cancer (abstract 808P): In this phase III trial, post-operative patients were randomized to a physician-choice adjuvant treatment plan prior to receiving MRD results to assess impact. The analysis showed that Signatera results influenced a change to providers' pre-planned treatment for one in three patients, of which 87% were treatment de-escalated based on MRD negativity.

  • Colorectal/Breast cancer (abstract 4258P): In a retrospective analysis of surveillance monitoring of stage I-III breast and colorectal cancer survivors, serial Signatera negativity was associated with an extremely low 2-year recurrence risk, which may help refine risk stratification and inform eligibility for solid organ transplant earlier than current methodologies.

  • Breast cancer (abstract 1770RO): In HER2+ metastatic breast cancer, an analysis of exceptional responders on anti-HER2 therapy showed 81% with sustained MRD-negativity during serial monitoring, supporting the potential for Signatera-guided de-escalation.

  • MDT-Bridge trial in non-small cell lung cancer (NSCLC) (abstract LBA62): This phase II trial evaluated MRD clearance from baseline to pre-surgery/pre-CRT using the Clarity™ assay with phased variant technology.

  • MRD-guided reflex to liquid CGP drives actionable treatment decisions (abstract 4260P): In a cohort of 50 patients across 10 tumor types, Signatera, complemented by reflex to blood-based comprehensive genomic profiling (liquid CGP), identified clinically relevant biomarkers in 18 patients, including ESR1, BRAF, FGFR3, and BRCA2.

  1. HealthcareIncyteIncyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026Companies: IncyteFour rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA33890 1 , a TGFβR2×PD-1 bispecific antibody Both investigational therapies are being evaluated in ongoing Phase 3 programs Incyte will host an investor event and webcast on Monday, October 26, 2026 from 7:30 – 9:00 C
  2. FinanceVeradermics, IncorporatedVeradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair LossConference call will take place on Monday, October 19, 2026, at 8:00 am ET NEW HAVEN, Conn., October 18, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it wi
  3. Real estateKaleon S.p.A. Announces the Passing of Chairman Vitaliano Borromeo AreseMILAN, October 18, 2026--Regulatory News: Kaleon S.p.A. (Paris:ALKLN) (MIL:KLN) announces with deep sorrow the passing of its Chairman of the Board of Directors, Vitaliano Borromeo. An entrepreneur with extensive experience in the industrial, real estate and financial sectors, since 2011 he had dedicat
  4. FinanceEvercoreEvercore Appoints Nigel Dawn and Naveen Nataraj as Co-PresidentsCo-President roles will add senior leadership depth as Evercore advances its strategic priorities NEW YORK, October 18, 2026--Evercore (NYSE: EVR) today announced that its Board of Directors has appointed Nigel Dawn and Naveen Nataraj as Co-Presidents of the firm, effective January 1, 2027. Mr. Dawn an
  5. RetailJapan & South Korea Divided by Drinking Habits, Finds IWSRIWSR's Bevtrac survey of consumer behaviour finds Japanese consumers less likely to drink alcohol and Koreans more likely to socialise while drinking LONDON, October 18, 2026--According to the latest IWSR Bevtrac survey, 76% of South Korean respondents of legal drinking age and above reported consuming
  6. HealthcareChildren's Hospital Los AngelesChildren’s Hospital Los Angeles Gala Celebrates Historic $1.35 Billion Anniversary Campaign MilestoneMichael Bublé Delivers Special Performance at the Celebration Hosted by Gina Rodriguez and Honoring Ellen K and Kourtney & Justin Turner LOS ANGELES, October 18, 2026--Children's Hospital Los Angeles (CHLA) celebrated a defining milestone in its 125-year history at the 2026 CHLA Gala, announcing the s